Blood test may Fine-Tune IVIg dosing for rare nerve disorders
NCT ID NCT04356781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 20 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were starting intravenous immunoglobulin (IVIg) treatment. Researchers measured changes in IgG levels in the blood after the first dose to see if those changes could predict the long-term dose each patient would need. The goal is to make dosing more precise, reduce side effects, and lower costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulin (IVIg)
- What this could lead to
- If successful, this could help doctors find the right IVIg dose for each patient more quickly, saving time and reducing side effects.
- What could go wrong
- This is a small, completed observational study with only 20 participants. It does not test a new treatment, so it may not lead to changes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Walton Centre NHS Foundation Trust
Liverpool, Merseyside, L9 7LJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for teens with rare nerve disease: drug trial launches
- New drug aims to thicken nerves and strengthen grip in rare nerve disorder
- New nerve patch could ease pain after biopsy
- New drug aims to keep rare nerve disease in check long-term
- Engineered immune cells take aim at multiple sclerosis and myasthenia gravis
- Massive Real-World study to track brain and nerve autoimmune disorders